Genet Med. 2012 Oct 4. doi: 10.1038/gim.2012.103. [Epub ahead of print]
Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.
SourceCenter for Medical Technology Policy, Baltimore, Maryland, USA.
AbstractPurpose:Prioritization of translational research on genomic tests is critically important given the rapid pace of innovation in genomics. The goal of this study was to evaluate a stakeholder-informed priority-setting framework in cancer genomics.Methods:An external stakeholder advisory group including patients/consumers, payers, clinicians, and test developers used a modified Delphi approach to prioritize six candidate cancer genomic technologies during a 1-day meeting. Nine qualitative priority-setting criteria were considered. We used a directed, qualitative content-analysis approach to investigate the themes of the meeting discussion.Results:Stakeholders primarily discussed six of the original nine criteria: clinical benefits, population health impacts, economic impacts, analytical and clinical validity, clinical trial implementation and feasibility, and market factors. Several new priority-setting criteria were identified from the workshop transcript, including "patient-reported outcomes," "clinical trial ethics," and "trial recruitment." The new criteria were incorporated with prespecified criteria to develop a novel priority-setting framework.Conclusion:This study highlights key criteria that stakeholders can consider when prioritizing comparative effectiveness research for cancer genomic applications. Applying an explicit priority-setting framework to inform investment in comparative effectiveness research can help to ensure that critical factors are weighed when deciding between many potential research questions and trial designs.Genet Med advance online publication 4 October 2012.Genetics in Medicine (2012); doi:10.1038/gim.2012.103.
- [PubMed - as supplied by publisher]